Skip to content
value.today

Celularity Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Biotechnology: $60 M to $268 M, median $131 M$0 M$72 M$145 M$217 M$289 MMarket value $28 M

Your own DCF model

A full discounted-cash-flow model of Celularity Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times Celularity Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Celularity Inc.Applied toValue (25th to 75th)Companies
Price to sales2.2× / 5.0× / 10.1×1.5×revenue $27 M$60 M to $268 M85

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Celularity Inc.'s multiples at each month end with a market cap on file, Jan 2022 to Oct 2026, each against its own median.

Price to sales

1.5×

Now above its median of 1.1×; range 0.5× to 39.8× over 27 months.

0×10×20×30×40×2023202420252026Price to sales 1×Median 1×

Price to book

3.7×

Now below its median of 4.1×; range 0.3× to 10.4× over 19 months.

0×3×5×8×10×2023202420252026Price to book 4×Median 4×

as of Oct 30, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 30, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$27 M$-92 M$-13 M———SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$54 M$-58 M$-6 M$0 M$-7 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$23 M$-196 M$-39 M$1 M$-40 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$18 M$14 M$-138 M$5 M$-143 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$21 M$-100 M$-110 M$6 M$-116 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$14 M$-208 M$-63 M$28 M$-91 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $28 M on Oct 30, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.